Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Studies from AIDS Center have provided new data on HIV/AIDS
June 3rd, 2009
"We previously reported that cynomolgus monkeys vaccinated with the human immunodeficiency virus (HIV)-1 Tat protein controlled infection after challenge with the simian human immunodeficiency virus (SHIV) 89.6P(cy243) for up to 2 y of follow-up. To evaluate the breadth of the protective immunity elicited by the Tat protein, the vaccines along with the naive monkeys were intravenously rechallenged with a fivefold higher dose (50 MID50) of the same SHIV-89.6P(cy243)," scientists in Rome, Italy report. "The vaccinated monkeys exhibited a statistically significant and long-lasting reduction of viral replication compared to control monkeys. This effect was associated with a...
Source: Vaccine Weekly (2009-06-03)
|
